The optimization of tamoxifen citrate entrapment and its release from biodegradable poly(d,l) lactic acid nanoparticles are prepared by modified spontaneous emulsification solvent diffusion method. Since the addition of tamoxifen citrate induces the formation of drug crystals from nanoparticle suspension the influence of several parameters on tamoxifen citrate encapsulation was investigated. In vitro studies for cytotoxicity, DNA ladder, and the expression of Bcl-2–Bax expression were also investigated for MCF-7 and MDA-MB-231 cells after the addition of tamoxifen citrate alone and tamoxifen citrate–poly(d,l) lactic acid–nanoparticles (encapsulated tamoxifen citrate). From results, it was noticed that the size and zeta potential of the drug loaded nanoparticles were not differed much in their physicochemical properties from drug free counterparts. The drug-loaded and drug-free nanoparticles exhibited size of in between 271.4 and 282.7 nm and zeta potential of −34 to −27.4 mV, respectively. There was significant increase in drug incorporation in the particles noticed in dichloromethane + methanol system in comparison to acetone + methanol and ethyl acetate + methanol systems. The drug was partly released from the nanoparticles after 48 h of incubation at 37℃. From Fourier transform infrared spectroscopy and differential scanning calorimetry data demonstrated drug–polymer characteristics within the nanoparticles and unincorporated drug that appeared in the form of crystals from polarized microscopic study. MCF-7 and MDA-MB-231 cells were more sensitive to tamoxifen citrate–poly(d,l) lactic acid–nanoparticles than tamoxifen citrate alone. DNA ladder and the expression of Bax to Bcl-2 ratio were much higher in tamoxifen citrate encapsulated in nanoparticles than that in tamoxifen citrate alone. These results demonstrated the feasibility of encapsulation of tamoxifen citrate and its enhanced efficiency in vitro and in vivo studies.
MacGregorJIJordanVC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev1998; 50: 151–196.
2.
MagarianRAOveracreLBSinghS. The medicinal chemistry of nonsteroidal antiestrogens: a review. Curr Med Chem1994; 1: 61–104.
3.
SarwaKKSureshPKDebnathM. Tamoxifen citrate loaded ethosomes for transdermal drug delivery system: preparation and characterization. Curr Drug Deliv2013; 10: 466–476.
4.
ElnaggarYSEl-MassikMAAbdallahOY. Self-nanoemulsifying drug delivery systems of tamoxifen citrate: design and optimization. Int J Pharm2009; 380: 133–141.
5.
O'ReganRMJordanVC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol2002; 3: 207–214.
6.
BonneterreJThurlimannBRobertsonJFR. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol2000; 18: 3748–3757.
7.
CameronDARitchieAALangdonS. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat1997; 45: 99–107.
8.
OsborneCK. Drug therapy—tamoxifen in the treatment of breast cancer. N Engl J Med1998; 339: 1609–1618.
9.
RavdinPMGreenSDorrTM. Prognostic-significance of progesterone-receptor levels in estrogen receptor-positive patients with metastatic breast-cancer treated with tamoxifen—results of a prospective Southwest-Oncology-Group Study. J Clin Oncol1992; 10: 1284–1291.
10.
ElefsiniotisISPantazisKDIliasA. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: the role of glucose intolerance. Eur J Gastroenterol Hepatol2004; 16: 593–598.
11.
SimeoneAMEkmikcioluSGrimmEA. A novel mechanism by which retinamide inhibits breast cancer growth: the production of nitric oxide. Mol Cancer Ther2002; 1: 1009–1017.
12.
WilliamsGMIatropoulosMJDjordjevicMV. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis1993; 14: 315–327.
13.
DesaiPNallaniSSaneR. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos2002; 30: 608–612.
14.
FarrelGC. Drugs and steatohepatitis. Semin Liver Dis2002; 22: 85–194.
15.
TabassumHRehmanHBanerjeeBD. Attenuation of tamoxifen-induced hepatotoxicity by taurine in mice. Clin Chim Acta2006; 370: 129–136.
16.
ClarkeMCollinsRDaviesC. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet1998; 351: 1451–1467.
17.
RutqvistLEJohanssonHSignomklaoT. Adjuvant tamoxifen therapy for early-stage breast cancer and 2nd primary malignancies. J Natl Cancer Inst1995; 87: 645–651.
18.
FisherBDignamJBryantJ. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst1996; 88: 1529–1542.
19.
KisangaERGjerdeJGuerrieri-GonzagaA. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res2004; 10: 2336–2343.
20.
HuFXNeohKGKangET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials2006; 27: 5725–5733.
21.
O'ReganRMJordanVC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol2002; 3: 207–214.
22.
BonneterreJThurlimannBRobertsonJFR. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol2000; 18: 3748–3757.
23.
CameronDARitchieAALangdonS. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat1997; 45: 99–107.
24.
de LimaGRFacinaGShidaJY. Effects of low dose tamoxifen on normal breast tissue from premenopausal women. Eur J Cancer2003; 39: 891–898.
Peters-EnglCFrankWDanmayrE. Association between endometrial cancer and tamoxifen treatment of breast cancer. Breast Cancer Res Treat1999; 54: 255–260.
27.
SahanaBSantraKBasuS. Development of biodegradable polymer based tamoxifen citrate loaded nanoparticles and effect of some manufacturing process parameters on them: a physicochemical and in-vitro evaluation. Int J Nanomed2010; 5: 621–630.
BazileDVRopertCHuveP. Bodydistribution of fully biodegradable 14C-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials1992; 13: 1093–1102.
30.
MakinoKArakawaMKondoT. Preparation and in vitro degradation properties of polylactide microcapsules. Chem Pharm Bull1985; 33: 1195–1201.
31.
RodriguesJMJrCroftSLFessiH. The activity and ultrastructural localization of primaquine-loaded poly (D, L-lactide) nanoparticles in Leishmania donovani infected mice. Trop Med Parasitol1994; 45: 223–228.
32.
RodriguesJMJrFessiHBoriesC. Primaquine loaded poly (lactide) nanoparticles: physicochemical study and acute tolerance in mice. Int J Pharm1995; 126: 253–260.
33.
Leroueil-Le VergerMFluckigerLKimY-I. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm1998; 46: 137–143.
34.
ChornyMFishbeinIDanenbergHD. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Rel2002; 83: 389–400.
35.
WehrlePMagenheimBBenitaS. The influence of process parameters on the PLA nanoparticle size distribution, evaluated by means of factorial design. Eur J Pharm Biopharm1995; 4: 19–26.
36.
GuterresSSFessiHBarrattG. Poly (D, L-lactide) nanocapsules containing diclofenac: I. Formulation and stability study. Int J Pharm1995; 113: 57–63.
37.
CauchetierEDeniauMFessiH. Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics. Int J Pharm2003; 250: 273–281.
38.
GiannavolaCBucoloCMalteseA. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res2003; 20: 584–590.
39.
Santos-MagalhãesNSFessiHPuisieuxF. An in vitro release kinetic examination and comparative evaluation between submicron emulsion and polylactic acid nanocapsules of clofibride. J Microencapsul1995; 12: 195–205.
40.
MusumeciTVenturaCAGiannoneI. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm2006; 325: 172–179.
41.
LayreA-MGrefRRichardJ. Nanoencapsulation of a crystalline drug. Int J Pharm2005; 298: 323–327.
42.
BilatiUAllemannEDoelkerE. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci2005; 24: 67–75.
43.
MosqueiraVCFLegrandPPinto-AlphandaryH. Poly (d,l-lactide) nanocapsules prepared by a solvent displacement process: influence of the composition on physicochemical and structural properties. J Pharm Sci2000; 89: 614–626.
44.
LemoineDFrancoisCKedzierewiczF. Stability study of nanoparticles of poly (ε-caprolactone), poly(d,l-lactide) and poly(d,l-lactideco-glycolide). Biomaterials1996; 17: 2191–2197.
45.
LiuMXDongJYangYJ. Research on system of triptolide-loaded poly (d,l-lactic acid) nanoparticles. J China Pharm University2004; 35: 117–121.
46.
RavikumaraNRNagarajTSHiremat ShobharaniR. Preparation and evaluation of nimesulide-loaded ethylcellulose and methylcellulose nanoparticles and microparticles for oral delivery. J Biomat Appl2009; 24: 47–64.
47.
RavikumaraNRMadhusudhanB. Evaluation of anticancer efficacy of daidzein loaded poly (D, L) lactic acid nanoparticles. J Bionanosci2012; 5: 1–8.
48.
RavikumaraNRTiyaboonchaiWMadhusudhanB. Fabrication and characterization of genistein encapsulated poly (D, L) lactic acid nanoparticles for pharmaceutical application. Curr Nanosci2013; 9: 293–302.
49.
DuaneTBirnbaum JacquelineDKosmala. Optimization of preparation techniques for poly (lactic acid-co-glycolic acid) nanoparticles. J Nanopart Res2000; 2: 173–181.
50.
MainardesRMEvangelistaRC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm2005; 290: 137–144.
51.
VippaguntaSRMaulKATallavajhalaS. Solid-state characterization of nifedipine solid dispersions. Int J Pharm2002; 236: 111–123.
52.
HancockBCCarlsonGTLadipoDD. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm2002; 241: 73–85.
53.
CorriganDOHealyAMCorriganOI. The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int J Pharm2003; 262: 125–137.
54.
ZilbermanMSchwadeNDMeidellRS. Structured drug-loaded bioresorbable films for support structures. J Biomater Sci Polym Ed2001; 12: 875–893.
55.
ZilbermanM. Dexamethasone loaded bioresorbable films used in medical support devices: structure, degradation, crystallinity and drug release. Acta Biomater2005; 1: 615–624.
56.
MajiRDeyNSSatapathyBS. Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy. Int J Nanomed2014; 9: 3107–3118.
57.
LiXYMaraniMMannucciR. Overexpression of BCL-XL underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res2001; 61: 1699–1706.
58.
LiuRItohTAraiKI. Two distinct signaling pathways downstream of Janus kinase play redundant roles for anti-apoptotic activity of granulocyte-macrophage colony-stimulating factor. Mol Biol Cell1999; 10: 3959–3970.
59.
BartlettDWSuHHildebrandtIJ. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA2007; 104: 15549–15554.
60.
HeurtaultBSaulnierPPechB. Physico-chemical stability of colloidal lipid particles. Biomaterials2003; 24: 4283–4300.
